The researchers examined de-identified data of 954,838 CPAP users from a remote monitoring network, who were registered for its patient engagement tool in the USA. The study found significant differences in 1-year adherence between people of different ages and disease severity levels:
- Overall adherence at 1 year was 70.4%.
- Men with sleep apnoea were 8.3% more likely to stay adherent on PAP therapy than women.
- People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs 70.4%).
- People with self-reported severe sleep apnoea (apnoea-hypopnoea index [AHI] ≥30/h) were 78% adherent at the 1-year mark, compared with 70.5% of those with self-reported moderate sleep apnoea (AHI 15-30/h), and 65% of those with mild sleep apnoea (AHI 5-15/h).
The study points to gaps in adherence to CPAP therapy for sleep apnoea indicating an unmet need for improved support, especially in women, younger patients, and those with mild disease.
- Armitstead JP. A2600, ATS 2019, 17-22 May, Dallas, USA.
Posted on
Previous Article
« Stem cell therapy in acute respiratory distress syndrome improves 28-day mortality Next Article
Human lung organoids to study foetal RSV infection »
« Stem cell therapy in acute respiratory distress syndrome improves 28-day mortality Next Article
Human lung organoids to study foetal RSV infection »
Table of Contents: ATS 2019
Featured articles
Letter from the Editor
Interview with Prof. Christian Bergmann
Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics
Treatable traits in chronic inflammatory airway disease: back to basics
Critical Care Medicine
Distinguishing between 4 different subtypes of sepsis sets the stage for individualised treatment
Stem cell therapy in acute respiratory distress syndrome improves 28-day mortality
SPICE III trial: Early sedation with dexmedetomidine in critically ill patients
SAATELLITE trial: Suvratoxumab prevents ventilator-associated Staphylococcus Aureus pneumonia in intensive care unit patients
Sleep Medicine
Million-patient study reveals gaps in long-term adherence among various sub-populations
Sleep apnoea severity has a non-linear relationship with acute myocardial infarction risk
Obstructive sleep apnoea affects morning spatial navigational memory processing in asymptomatic older individuals
Pulmonary Vascular Disease and Interstitial Lung Disease
Nintedanib reduces lung function decline in systemic sclerosis-associated ILD
Pulmonary arterial hypertension: early treatment with selexipag most effective
Long-term safety and efficacy of recombinant human pentraxin-2 in patients with idiopathic pulmonary fibrosis
Infection
Dupilumab improves outcomes in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma
Durability of culture conversion in patients receiving ALIS for treatment-refractory MAC lung disease
E-cigarette use disrupts normal immune response to viral infections, particularly in women
Paediatric Pulmonary Medicine
Bacterial pneumonia predicts ongoing lung problems in infants hospitalised for acute respiratory failure
Aspergillus and early cystic fibrosis lung disease: does it need to be treated?
COPD
CORTICO-COP trial: eosinophil-guided therapy reduces systemic corticosteroid exposure
A randomised controlled trial of a smoking cessation smartphone application
Benralizumab does not ameliorate COPD exacerbations (GALATHEA/TERRANOVA trials)
Aclidinium bromide delays COPD exacerbation without increased MACE risk
Bench-to-Bedside (Pre-Clinical)
Human lung organoids to study foetal RSV infection
CRISPR/Cas9 genome editing therapy of hereditary pulmonary alveolar proteinosis
Cilia diagnostics in primary ciliary dyskinesia
Tuberous sclerosis complex 2 may be a novel target in pulmonary arterial hypertension therapy
Related Articles
August 18, 2021
Hypertension pathology visible in white matter lesion volume
September 10, 2020
Intensive hypertension treatment lowers risk of orthostatic hypotension
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com